News

Amyotrophic lateral sclerosis (ALS) is a complex disease with varying symptoms and severity for people affected. Due to its heterogeneity, diagnosing the disease can be challenging and finding effective treatments can also be difficult. CAPTURE (Comprehensive…

Funding for first two projects to total $200,000 Toronto – Amyotrophic lateral sclerosis (ALS) is a disease that can progress with startling swiftness. The ALS Society of Canada (ALS Canada) recognizes the need to move quickly in funding promising research…

In Canada, what the provincial health care systems provide does not always match the needs of people living with ALS. This statement rings true for Ontario, where the current ALS care and support landscape in the province presents people living…

Updated on: January 31, 2024 Pharmaceutical company Ferrer has announced topline results from the ADORE (ALS Deceleration with ORral Edaravone) clinical trial in ALS. The Phase 3 study, conducted in Europe, investigated the efficacy of an oral formulation of edaravone…

As we bid farewell to 2023, we want to take a moment to celebrate YOU. Your dedication throughout this month, and indeed the entire year, has been nothing short of inspirational. As a community, you have rallied together to show…

The province of Manitoba has listed RADICAVA Oral Suspension on the Manitoba Pharmacare Program (Exceptional Drug Status) as a treatment for ALS. With this announcement, all provinces and territories across Canada – as well as Veterans Affairs Canada and Indigenous…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

A letter from Tammy Moore, ALS Canada’s Chief Executive Officer Let me start by saying thank you. Thank you for standing beside us throughout the year, driven by our shared vision: a future without ALS. Today, I want to…